Payment overview · 2025
General Payments
$625.98
36 reported records · 18 companies
Healthcare provider profile · identity verified
Daniel J. Owens, MD
Allopathic & Osteopathic Physicians|Family Medicine · FLORENCE, SC · NPI 1104828144
Verified facts
What the public records show
CMS Open Payments records show Daniel J. Owens, MD received $625.98 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.33 | 12.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.34 | 12.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.47 | 9.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.92 | 8.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.00 | 7.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $43.76 | 7.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.20 | 6.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.26 | 5.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.14 | 5.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.31 | 5.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.01 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.56 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.19 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.49 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.21 | 2.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.45 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.17 | 2.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $14.17 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $625.98 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $53.92 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.39 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.00 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $43.76 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 143 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 517 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 460 | 53 |
| Gabapentin | Gabapentin | 399 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 87 |
| Alprazolam | Alprazolam | 395 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 387 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 305 | 84 |
| Losartan Potassium | Losartan Potassium | 286 | 72 |
| Metformin Hcl | Metformin Hcl | 257 | 71 |
| Omeprazole | Omeprazole | 255 | 70 |
| Prednisone | Prednisone | 254 | 148 |
| Pregabalin | Pregabalin | 238 | 43 |
| Furosemide | Furosemide | 230 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 54 |
| Montelukast Sodium | Montelukast Sodium | 184 | 50 |
| Lisinopril | Lisinopril | 181 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 176 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 53 |
| Potassium Chloride | Potassium Chloride | 168 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 35 |
| Ozempic | Semaglutide | 155 | 26 |
| Jardiance | Empagliflozin | 147 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 142 | 15 |
| Carvedilol | Carvedilol | 136 | 39 |
| Clonazepam | Clonazepam | 134 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 38 |
| Sertraline Hcl | Sertraline Hcl | 130 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 32 |
| Tramadol Hcl | Tramadol Hcl | 127 | 33 |
| Eliquis | Apixaban | 125 | 33 |
| Trazodone Hcl | Trazodone Hcl | 124 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 28 |
| Famotidine | Famotidine | 114 | 22 |
| Ibuprofen | Ibuprofen | 112 | 31 |
| Nifedipine Er | Nifedipine | 110 | 26 |
| Allopurinol | Allopurinol | 107 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 29 |
| Clonidine Hcl | Clonidine Hcl | 104 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 32 |
| Metformin Hcl Er | Metformin Hcl | 103 | 30 |
| Meclizine Hcl | Meclizine Hcl | 101 | 30 |
| Meloxicam | Meloxicam | 100 | 32 |
| Glipizide Er | Glipizide | 96 | 21 |
| Farxiga | Dapagliflozin Propanediol | 95 | 18 |
| Spironolactone | Spironolactone | 89 | 28 |
| Ezetimibe | Ezetimibe | 85 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 23 |
| Simvastatin | Simvastatin | 78 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 48 |
| Glipizide | Glipizide | 77 | 20 |
| Chlorthalidone | Chlorthalidone | 73 | 25 |
| Colchicine | Colchicine | 73 | 19 |
| Promethazine Hcl | Promethazine Hcl | 73 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 15 |
| Linzess | Linaclotide | 70 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 32 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Mirtazapine | Mirtazapine | 64 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 62 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 37 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Estradiol | Estradiol | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Sucralfate | Sucralfate | 52 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 13 |
| Novolog Flexpen | Insulin Aspart | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Irbesartan | Irbesartan | 49 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Finasteride | Finasteride | 48 | 13 |
| Temazepam | Temazepam | 48 | 11 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 46 | 13 |
| Fluconazole | Fluconazole | 45 | 26 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | suppressed |
| Azithromycin | Azithromycin | 42 | 33 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 12 |
| Bumetanide | Bumetanide | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Klor-Con M20 | Potassium Chloride | 34 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 11 |
| Naproxen | Naproxen | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Nystatin | Nystatin | 31 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 12 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Dofetilide | Dofetilide | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Norvasc | Amlodipine Besylate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $625.98 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error